AI Engines For more Details: Perplexityβ Kagi Labsβ Youβ
Smooth Muscle Relaxation: Alverine citrate works by exerting a smooth muscle relaxant effect on the gastrointestinal tract, particularly on the smooth muscle of the intestines. It helps reduce intestinal spasms, cramping, and associated symptoms such as abdominal pain and discomfort.
Treatment of Irritable Bowel Syndrome (IBS): Alverine citrate is commonly used in the treatment of irritable bowel syndrome (IBS), a functional gastrointestinal disorder characterized by abdominal pain or discomfort, bloating, and altered bowel habits. It can help alleviate symptoms associated with IBS, such as abdominal cramps and spasms, and improve overall bowel function.
Symptomatic Relief: Alverine citrate provides symptomatic relief of gastrointestinal symptoms associated with functional bowel disorders, including IBS with predominant symptoms of abdominal pain and spasms. It helps improve quality of life by reducing the frequency and severity of symptoms and improving bowel regularity.
Antispasmodic Action: As an antispasmodic agent, alverine citrate helps reduce excessive contractions of the intestinal muscles, which can contribute to abdominal pain, cramping, and bloating. It promotes smooth muscle relaxation and normalization of bowel motility, leading to relief of symptoms.
Adjunctive Therapy: Alverine citrate is often used as adjunctive therapy in combination with dietary and lifestyle modifications for the management of IBS and functional bowel disorders. It may be used in conjunction with other medications such as antidiarrheal agents or fiber supplements to optimize symptom control and improve patient outcomes.
Safety Profile: Alverine citrate is generally well tolerated when used as directed. Common side effects may include dizziness, headache, nausea, and dry mouth. These side effects are usually mild and transient and may resolve with continued use or dose adjustments.
Contraindications: Alverine citrate is contraindicated in individuals with known hypersensitivity to the drug or its components. It should not be used in patients with severe liver impairment or severe kidney impairment, as data on safety and efficacy in these populations are limited.
Pregnancy and Lactation: The safety of alverine citrate use during pregnancy and breastfeeding has not been well established. It is generally recommended to avoid using alverine citrate during pregnancy unless the potential benefits outweigh the risks, and under the guidance of a healthcare professional.
Drug Interactions: Alverine citrate may interact with certain medications, including anticholinergic drugs and other medications that affect gastrointestinal motility. Concomitant use of these medications may potentiate or diminish the effects of alverine citrate and should be used with caution.
(meteospasmyl, pms-sparenil, spasmonal forte, alve, alverine, avarin, averine, dismonal, gastro-intestinal, mΓ©tΓ©ospasmyl, nady-spasmyl, profenil, savory, soverine, spasdipyrin, spasmaverine, spasmine, spasmine forte, spasmium, spasmol, spasmolina, spasmonal, spaspa, spastin, spasverin, spasverine)
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Pseudomonas sp. cn4902 | Reduces |
species group | Pseudomonas putida group | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
2 | 0 | Staphylococcus aureus | species | Decreases |
2 | 0 | Escherichia coli | species | Decreases |
1 | 1 | Escherichia | genus | Decreases |
1 | 1 | Staphylococcus | genus | Decreases |
1 | 0 | Kluyvera | genus | Decreases |
1 | 0 | Pseudomonas | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive β X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
Acne | 1.5 | 0.9 | 0.67 |
ADHD | 2.9 | 0.6 | 3.83 |
Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
Allergic Rhinitis (Hay Fever) | 4 | 2.4 | 0.67 |
Allergies | 6.8 | 4 | 0.7 |
Allergy to milk products | 2.5 | 1.1 | 1.27 |
Alopecia (Hair Loss) | 1.5 | 1.5 | |
Alzheimer's disease | 4.8 | 5.8 | -0.21 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.8 | 1.4 | 1.71 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. β Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA β Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. β Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. β Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.217 ]